World Pharma News Digest - 16.04.2012
2 views
Skip to first unread message
Ruslan David
Apr 16, 2012, 4:48:17 AM4/16/12
to worldph...@googlegroups.com
Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
Read more...
http://www.worldpharmanews.com/contact-us
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
Read more...
http://www.worldpharmanews.com/contact-us
Discovery could help to develop drugs for organ transplant and cancer patients
Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others. The finding eventually could lead to new drugs to regulate the immune system by, for example, revving it up to attack tumor cells or tamping it down to prevent the rejection of transplanted organs.
Read more...
http://www.worldpharmanews.com/research/2043-discovery-could-help-to-develop-drugs-for-organ-transplant-and-cancer-patients
Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others. The finding eventually could lead to new drugs to regulate the immune system by, for example, revving it up to attack tumor cells or tamping it down to prevent the rejection of transplanted organs.
Read more...
http://www.worldpharmanews.com/research/2043-discovery-could-help-to-develop-drugs-for-organ-transplant-and-cancer-patients
Roche on track for full-year targets - good sales growth in first quarter
In the first three months of 2012 Group sales rose 2% in constant currencies to 11.0 billion Swiss francs. The Pharmaceuticals Division's sales increased 2% to 8.6 billion Swiss francs. Excluding Tamiflu, sales for the Group and Pharma rose 3%.
Read more...
http://www.worldpharmanews.com/roche/2042-roche-on-track-for-full-year-targets-good-sales-growth-in-first-quarter
In the first three months of 2012 Group sales rose 2% in constant currencies to 11.0 billion Swiss francs. The Pharmaceuticals Division's sales increased 2% to 8.6 billion Swiss francs. Excluding Tamiflu, sales for the Group and Pharma rose 3%.
Read more...
http://www.worldpharmanews.com/roche/2042-roche-on-track-for-full-year-targets-good-sales-growth-in-first-quarter
UCLA-engineered stem cells seek out and kill HIV in living organisms
Expanding on previous research providing proof-of-principal that human stem cells can be genetically engineered into HIV-fighting cells, a team of UCLA researchers have now demonstrated that these cells can actually attack HIV-infected cells in a living organism.
Read more...
http://www.worldpharmanews.com/research/2041-ucla-engineered-stem-cells-seek-out-and-kill-hiv-in-living-organisms
Expanding on previous research providing proof-of-principal that human stem cells can be genetically engineered into HIV-fighting cells, a team of UCLA researchers have now demonstrated that these cells can actually attack HIV-infected cells in a living organism.
Read more...
http://www.worldpharmanews.com/research/2041-ucla-engineered-stem-cells-seek-out-and-kill-hiv-in-living-organisms
Takeda to Acquire URL Pharma
Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma - a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments.
Read more...
http://www.worldpharmanews.com/takeda/2040-takeda-to-acquire-url-pharma
Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma - a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments.
Read more...
http://www.worldpharmanews.com/takeda/2040-takeda-to-acquire-url-pharma
UCB marks World Parkinson's Disease Day with new Parkinson's Well-Being Map™
UCB is announcing a new initiative for World Parkinson's Disease Day 2012 that is designed to support communication around all aspects of Parkinson's Disease (PD). The Parkinson's Well-Being Map™ is a visual tool designed to help people with PD discuss their health status and well-being with their care teams.
Read more...
http://www.worldpharmanews.com/ucb/2039-ucb-marks-world-parkinsons-disease-day-with-new-parkinsons-well-being-map
UCB is announcing a new initiative for World Parkinson's Disease Day 2012 that is designed to support communication around all aspects of Parkinson's Disease (PD). The Parkinson's Well-Being Map™ is a visual tool designed to help people with PD discuss their health status and well-being with their care teams.
Read more...
http://www.worldpharmanews.com/ucb/2039-ucb-marks-world-parkinsons-disease-day-with-new-parkinsons-well-being-map
Alzheimer's precursor protein controls its own fate
A research team led by the University of South Florida Department of Psychiatry & Behavioral Neurosciences has found that a fragment of the amyloid precursor protein (APP) - known as sAPP-α and associated with Alzheimer's disease - appears to regulate its own production.
Read more...
http://www.worldpharmanews.com/research/2038-alzheimers-precursor-protein-controls-its-own-fate
A research team led by the University of South Florida Department of Psychiatry & Behavioral Neurosciences has found that a fragment of the amyloid precursor protein (APP) - known as sAPP-α and associated with Alzheimer's disease - appears to regulate its own production.
Read more...
http://www.worldpharmanews.com/research/2038-alzheimers-precursor-protein-controls-its-own-fate
Amgen to acquire privately held KAI Pharmaceuticals
Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.
Read more...
http://www.worldpharmanews.com/amgen/2037-amgen-to-acquire-privately-held-kai-pharmaceuticals
Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.
Read more...
http://www.worldpharmanews.com/amgen/2037-amgen-to-acquire-privately-held-kai-pharmaceuticals
Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used.
Read more...
http://www.worldpharmanews.com/research/2036-normalizing-tumor-blood-vessels-improves-delivery-of-only-the-smallest-nanomedicines
Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used.
Read more...
http://www.worldpharmanews.com/research/2036-normalizing-tumor-blood-vessels-improves-delivery-of-only-the-smallest-nanomedicines
PharmaNews.eu / Latest News
European regulators propose way forward for publication of full clinical trial data
http://www.pharmanews.eu/ema/1035-european-regulators-propose-way-forward-for-publication-of-full-clinical-trial-data
http://www.pharmanews.eu/ema/1035-european-regulators-propose-way-forward-for-publication-of-full-clinical-trial-data
Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)
http://www.pharmanews.eu/abbott/1034-abbotts-humirar-adalimumab-approved-in-europe-for-treatment-of-ulcerative-colitis-uc
http://www.pharmanews.eu/abbott/1034-abbotts-humirar-adalimumab-approved-in-europe-for-treatment-of-ulcerative-colitis-uc
Dangerous blood pressure medicine
http://www.pharmanews.eu/research-and-development/1033-dangerous-blood-pressure-medicine
http://www.pharmanews.eu/research-and-development/1033-dangerous-blood-pressure-medicine
The European Medicines Agency supports World Health Day
http://www.pharmanews.eu/ema/1032-the-european-medicines-agency-supports-world-health-day
http://www.pharmanews.eu/ema/1032-the-european-medicines-agency-supports-world-health-day
Novartis QVA149 Phase III COPD studies meet primary endpoints
http://www.pharmanews.eu/novartis/1031-novartis-qva149-phase-iii-copd-studies-meet-primary-endpoints
http://www.pharmanews.eu/novartis/1031-novartis-qva149-phase-iii-copd-studies-meet-primary-endpoints
Heart failure's effects in cells can be reversed with a rest
http://www.pharmanews.eu/research-and-development/1030-heart-failures-effects-in-cells-can-be-reversed-with-a-rest
http://www.pharmanews.eu/research-and-development/1030-heart-failures-effects-in-cells-can-be-reversed-with-a-rest
New survey by SFL and EuropaBio highlights poor awareness of HTA among biotech SMEs in Europe
http://www.pharmanews.eu/research-and-development/1029-new-survey-by-sfl-and-europabio-highlights-poor-awareness-of-hta-among-biotech-smes-in-europe
http://www.pharmanews.eu/research-and-development/1029-new-survey-by-sfl-and-europabio-highlights-poor-awareness-of-hta-among-biotech-smes-in-europe
With best regards,
Ruslan David
Administrator/Editor
Ruslan David
Administrator/Editor
PS: Download World Pharma News' Media Pack (.pdf, 214 KB) http://www.worldpharmanews.com/images/media_pack.pdf
Reply all
Reply to author
Forward
0 new messages